# reload+after+2024-01-22 02:45:25.039740
address1§92 Park Drive
address2§Milton Park
city§Abingdon
zip§OX14 4RY
country§United Kingdom
phone§44 12 3543 8600
website§https://www.immunocore.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also developing other programs for oncology comprise tebentafusp that is in Phase 2/3 clinical trial in patients with advanced melanoma; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising cutaneous melanoma, ovarian, non-small cell lung cancer, and endometrial; IMC-T119C for multiple solid tumor cancers; IMC-P115C for multiple solid tumor cancers; and IMC-R117C, which is for a range of tumors, including colorectal, gastro-esophageal, and pancreatic cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in Phase 1 clinical trial for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
fullTimeEmployees§408
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Bahija  Jallal Ph.D.', 'age': 61, 'title': 'CEO & Director', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 1417606, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Brian R. Di Donato M.B.A.', 'age': 56, 'title': 'CFO & Head of Strategy', 'yearBorn': 1967, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Annelise  Vuidepot Ph.D.', 'title': 'CTO and Head of Pipeline & Platform Research', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Clayton  Robertson', 'title': 'Head of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Lily Margaret Hepworth', 'title': 'General Counsel & Company Secretary', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Amy  Judge-Prein', 'title': 'Chief Compliance Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Sébastien  Desprez', 'title': 'Head of Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Tina St. Leger', 'age': 55, 'title': 'Chief Human Resources Officer & Director', 'yearBorn': 1968, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. David  Berman M.D., Ph.D.', 'age': 52, 'title': 'Head of Research & Development', 'yearBorn': 1971, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Debra  Nielsen', 'title': 'Chief of Staff', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.966
priceToSalesTrailing12Months§17.148987
currency§USD
dateShortInterest§1702598400
forwardEps§-1.64
exchange§NMS
quoteType§EQUITY
shortName§Immunocore Holdings plc
longName§Immunocore Holdings plc
firstTradeDateEpochUtc§1612535400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§b7b7552a-a3f9-3661-bcfc-03291a3fce2e
gmtOffSetMilliseconds§-18000000
targetHighPrice§92.45
targetLowPrice§60.29
targetMeanPrice§80.33
targetMedianPrice§83.41
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§16
quickRatio§4.12
earningsGrowth§-0.677
grossMargins§0.39628
ebitdaMargins§-0.27473
trailingPegRatio§None
